Stanley Riddell

Stanley Riddell, M.D., is a Professor at the University of Washington School of Medicine's Department of Immunology and holds the Burke O’Reilly Family Endowed Chair in Immunotherapy at Fred Hutchinson Cancer Research Center. He leads the Riddell Lab, focusing on adoptive T-cell therapy, CAR T-cell engineering, and overcoming tumor immune evasion. His work includes clinical trials targeting B-cell malignancies, solid tumors, and viral infections post-transplant. Key contributions include CD19 CAR T-cell therapy for leukemia/lymphoma and identification of tumor antigens like BRAFV600E. He collaborates with institutions like TUM School of Medicine and UW's Institute for Protein Design.

Education: MD from University of Manitoba (1979), residency/internal medicine (1983), hematology fellowship (1985). Clinical expertise includes stem cell transplantation and GVHD management. Awards include the American Cancer Society Research Professorship. His lab includes researchers like Josh Veatch, Carla Jaeger, and postdocs Tamer Shabaneh/Sylvain Simon.

Research spans immunotherapy safety, T-cell subset optimization, and neoantigen targeting. Current projects address solid tumor CAR T-cell challenges, ROR1-targeted therapies, and synthetic biology innovations.